News Axonics, Inc.

Equities

AXNX

US05465P1012

Real-time Estimate Cboe BZX Other stock markets 12:43:04 2024-04-24 pm EDT			5-day change	1st Jan Change
66.7 ^USD	+0.34%		-0.73%	+7.20%

Apr. 04	Boston Scientific, Axonics Receive FTC Second Request on Merger Deal	MT
Apr. 04	Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Boston Scientific, Axonics Receive FTC Second Request on Merger Deal	Apr. 04	MT
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information	Apr. 04	DJ
FTC seeks additional information for Boston Scientific's $3.7 bln Axonics deal	Apr. 04	RE
Axonics Stockholders Approve Merger Agreement with Boston Scientific	Mar. 25	AQ
Axonics Wins Shareholder Approval of Merger With Boston Scientific	Mar. 22	MT
Axonics Stockholders Approve Merger Agreement with Boston Scientific	Mar. 22	BU
Axonics to File for Review After Patent Board Invalidates Claims in Medtronic Case	Mar. 21	MT
Axonics Provides Update on Inter Partes Review Proceedings	Mar. 21	BU
Medtronic to Ask Court to Resume Patent Infringement Case Against Axonics After Favorable Patent Office Ruling	Mar. 21	MT
Axonics to Sell Rechargeable Sacral Neuromodulation System in Europe Starting April	Mar. 14	MT
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System	Mar. 14	BU
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Axonics Responds to ITC Action by Medtronic	Feb. 29	BU
Axonics Q4 Earnings, Revenue Rise -- Shares Edge Higher After Hours	Feb. 28	MT
Axonics: Q4 Earnings Snapshot	Feb. 28	AQ
Axonics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (AXNX) AXONICS Posts Q4 Revenue $109.7M	Feb. 28	MT
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results	Feb. 28	BU
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX	Feb. 27	BU
Boston Scientific Prices $2.17 Billion Euro-Denominated Notes Offering	Feb. 23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Axonics, Inc.

Equities

AXNX

US05465P1012

Summary

Filters